These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31347926)

  • 61. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study.
    Kaku K; Yamamoto K; Fukushima Y; Lliev H; Yasui A
    Expert Opin Drug Saf; 2022 Oct; 21(10):1315-1328. PubMed ID: 35315729
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
    Kutoh E; Wada A; Murayama T; Takizawa Y
    Drugs R D; 2017 Jun; 17(2):313-320. PubMed ID: 28285448
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
    Nagai Y; Ohta A; Sada Y; Kato H; Tanaka Y
    Expert Opin Pharmacother; 2017 Jan; 18(1):13-17. PubMed ID: 27841020
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
    Sugimoto K; Abe I; Minezaki M; Takashi Y; Ochi K; Fujii H; Ohishi H; Yamao Y; Kudo T; Ohe K; Abe M; Ohnishi Y; Shinagawa T; Mukoubara S; Kobayashi K
    Drug Discov Ther; 2019; 13(6):322-327. PubMed ID: 31956230
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
    Takahara M; Shiraiwa T; Matsuoka TA; Katakami N; Shimomura I
    Endocr J; 2015; 62(1):77-86. PubMed ID: 25328035
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
    Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
    Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance.
    Ito T; Naito Y; Shimmoto N; Ochiai K; Hayashi N; Okamura T
    Expert Opin Drug Saf; 2021 Mar; 20(3):363-372. PubMed ID: 33269625
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
    Diabetes Obes Metab; 2019 Aug; 21(8):1990-1995. PubMed ID: 30993861
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
    Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
    Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study).
    Matsuhisa M; Odawara M; Hirose T; Koshida R; Senda M; Tanaka Y; Terauchi Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):249-256. PubMed ID: 32840155
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
    Lu CH; Min KW; Chuang LM; Kokubo S; Yoshida S; Cha BS
    J Diabetes Investig; 2016 May; 7(3):366-73. PubMed ID: 27330723
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
    Toyoshima J; Saito M; Kaibara A; Isaka H; Sakatani T
    Clin Ther; 2020 Sep; 42(9):1787-1798.e3. PubMed ID: 32839028
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study.
    Shimoda M; Mashiko A; Katakura Y; Sanada J; Fushimi Y; Obata A; Kimura T; Kohara K; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    Endocr J; 2021 Dec; 68(12):1455-1461. PubMed ID: 34334532
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance.
    Moon JS; Kim NH; Na JO; Cho JH; Jeong IK; Lee SH; Mok JO; Kim NH; Chung DJ; Cho J; Lee DW; Lee SW; Won KC
    Diabetes Metab J; 2023 Jan; 47(1):82-91. PubMed ID: 35722684
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
    Kitazawa M; Katagiri T; Suzuki H; Matsunaga S; H Yamada M; Ikarashi T; Yamamoto M; Furukawa K; Iwanaga M; Hatta M; Fujihara K; Yamada T; Tanaka S; Sone H
    Diabetes Obes Metab; 2021 Mar; 23(3):811-821. PubMed ID: 33416200
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-Term Safety and Clinical Outcomes with Insulin Degludec/Insulin Aspart Treatment in Japanese Patients with Diabetes: A Real-World, Prospective, Observational Study.
    Katabami T; Eriksen KT; Yamamoto Y; Ishigaki Y
    Adv Ther; 2022 Jan; 39(1):544-561. PubMed ID: 34800283
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
    Tanaka M; Yamakage H; Inoue T; Odori S; Kusakabe T; Shimatsu A; Satoh-Asahara N
    Intern Med; 2020; 59(5):601-609. PubMed ID: 32115517
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
    Kaku K; Isaka H; Toyoshima J; Sakatani T
    Diabetes Obes Metab; 2019 Jun; 21(6):1445-1454. PubMed ID: 30821047
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
    Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
    Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.